ALNYLAM PHARMACEUTICALS, INC.
ALNY evidence brief
What we can confirm
- BioSniper Score:
- 4.8 / 10
- Market Cap:
- $33.09B
- Next Catalyst:
- Patent_Expiry · Oct 3, 2034
What it means
What to watch
Prepared research question
What matters most for ALNY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALNY
Alnylam Pharmaceuticals (ALNY) is a leading RNAi therapeutics company with approved products for transthyretin-mediated amyloidosis and a pipeline targeting cardiovascular and other diseases, reporting profitability and a strong cash position as of mid-2026.
Key risk: Revenue concentration risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 36 clinical trials · 4 catalysts for ALNYLAM PHARMACEUTICALS, INC..
Alnylam Pharmaceuticals (ALNY) is a leading RNAi therapeutics company with approved products for transthyretin-mediated amyloidosis and a pipeline targeting cardiovascular and other diseases, reporting profitability and a strong cash position as of mid-2026.
- Cash & equivalents of $1,708.3M as of 2026-06-30 [sec]
- Total revenue of $1,290.9M and net income of $164.5M as of 2026-06-30 [sec]
- Shareholders' equity of $1,354.1M as of 2026-06-30 [sec]
- Presented new clinical and real-world data on AMVUTTRA (vutrisiran) and investigational zilebesiran at ESC Congress 2026 [news · published 2026-08-30]
- Initiated Phase 1 trial for ALN-6222 in obesity (2026-06-04) and Phase 2 trial for ALN-6400 in von Willebrand disease (2026-07-30) [catalyst]
What works
- Strong cash position of $1,708.3M as of 2026-06-30 supports pipeline development and operations [sec]
- Achieved profitability with net income of $164.5M as of 2026-06-30 [sec]
- Broad pipeline with late-stage programs in ATTR amyloidosis and hypertension, and early-stage programs in obesity, von Willebrand disease, and Alzheimer's disease [news · published 2026-08-24][catalyst]
- Commercial momentum for AMVUTTRA in transthyretin-mediated cardiomyopathy [news · published 2026-09-20]
What to weigh
- Share price under pressure, down 41% year to date as of August 2026 [news · published 2026-08-24]
- Revised 2026 TTR franchise revenue outlook downward due to market changes [news · published 2026-09-20]
- Dependence on a few key products (AMVUTTRA, patisiran) for current revenue, with pipeline assets still in clinical development
From the filings
Quoted directly from source documents.
Alnylam is the leading RNAi therapeutics company
“Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company”
News · August 30, 2026
Zilebesiran is designed for twice-yearly dosing in hypertension
“designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk”
News · September 20, 2026
Catalyst timeline
- 2034-10-03 · Patent_Expiry · GIVOSIRAN SODIUM — Patent expiry for NDA212194; may open to generic competition.
- 2035-08-27 · Patent_Expiry · PATISIRAN SODIUM — Patent expiry for NDA210922; may open to generic competition.
- 2036-07-28 · Patent_Expiry · VUTRISIRAN SODIUM — Patent expiry for NDA215515; may open to generic competition.
- 2038-11-20 · Patent_Expiry · LUMASIRAN SODIUM — Patent expiry for NDA214103; may open to generic competition.
Risks & what to watch (3)›
Key risks
- Revenue concentration risk — Revenue depends heavily on TTR franchise (AMVUTTRA, patisiran); pipeline assets not yet commercialized [news · published 2026-09-20]
- Share price decline — Stock down 41% year to date as of August 2026, indicating market concerns [news · published 2026-08-24]
- Patent expirations approaching — Key patents for GIVOSIRAN (2034), PATISIRAN (2035), VUTRISIRAN (2036), LUMASIRAN (2038) will expire [catalyst]
What to watch
- New clinical and real-world data from ESC Congress 2026 on AMVUTTRA and zilebesiran [news · published 2026-08-30]
- Progress of zilebesiran in the ZENITH phase 3 trial for hypertension [news · published 2026-09-20]
- Phase 1/2 results for ALN-6400 in von Willebrand disease and hereditary hemorrhagic telangiectasia [catalyst]
- Phase 1 results for ALN-6222 in obesity [catalyst]
Sources: Catalysts · News · Generated October 13, 2026 · How we verify sources →
Run ALNYLAM PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ALNYLAM PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 3.11 · 4% dilution
No tracked pipeline phase
No tracked pipeline candidates
4 upcoming, next in ~2911d
0 buys · 5 sells (180d)
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
782
Total value held
$39.95B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 14,579,166 | $4.82B |
| capital world investors | 10,802,348 | $3.57B |
| blackrock, inc. | 10,444,908 | $3.46B |
| capital research global investors | 9,471,181 | $3.13B |
| vanguard portfolio management llc | 6,491,280 | $2.15B |
| jpmorgan chase & co | 6,323,752 | $2.00B |
| vanguard capital management llc | 5,946,706 | $1.97B |
| state street corp | 3,322,698 | $1.10B |
| geode capital management, llc | 2,660,385 | $884.6M |
| baillie gifford & co | 2,493,866 | $825.1M |
Showing top 10 of 782 institutional holders of ALNYLAM PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 5.0%
- Days to cover
- 4.4
- Shares short
- 5,034,063
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALNY short interestGovernance
Frequently asked questions
What is the AI investment thesis for ALNYLAM PHARMACEUTICALS, INC.?
Alnylam Pharmaceuticals (ALNY) is a leading RNAi therapeutics company with approved products for transthyretin-mediated amyloidosis and a pipeline targeting cardiovascular and other diseases, reporting profitability and a strong cash position as of mid-2026.
What is ALNYLAM PHARMACEUTICALS, INC.'s next catalyst?
ALNYLAM PHARMACEUTICALS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA212194" — expected October 3, 2034.
Who is the CEO of ALNYLAM PHARMACEUTICALS, INC.?
Dr. Yvonne L. Greenstreet M.B.A., M.D. is the chief executive officer of ALNYLAM PHARMACEUTICALS, INC. (ALNY).
Where is ALNYLAM PHARMACEUTICALS, INC. headquartered?
ALNYLAM PHARMACEUTICALS, INC. (ALNY) is headquartered in Cambridge, MA, United States.
What therapeutic areas does ALNYLAM PHARMACEUTICALS, INC. focus on?
ALNYLAM PHARMACEUTICALS, INC. develops therapies across Oncology, Rare Disease, Neurology, Cardiovascular, Metabolic, Dermatology, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.